About Cancer Commons
Founded in 2012, Cancer Commons is a patient-led, scientist-driven navigation service focused on rare, advanced, and treatment-resistant cancers where standard care falls short.
Current Opportunity
Our scientific team regularly informs clients about novel products, services, and testing options that could impact treatment decisions. We are actively seeking information from organizations to better educate our clients and their families.
We invite organizations to share details, publications, and validations on their products and services. Our PhD-led team will review submissions and follow up with relevant inquiries. Please complete this short online questionnaire.
The Future: Cancer Commons 2.0
We are building the Cancer Commons Research Network (CCRN), a decentralized platform enabling physicians to manage and study patients as n-of-1 cases. This will operate within a regulatory-grade registry under IRB, capturing real-world data and outcomes in near real-time.
Cancer Commons Services Network (CCSN)
As part of CCRN, we are assembling a network of service providers offering:
- Precision functional assays
- Molecular, immune, and multiomics testing
- Virtual molecular tumor boards
- Expanded access management
- Pharmacogenomics services
- Treatment decision-making tools
Our goal is to connect patients and providers with the most relevant services while offering partner companies a cost-effective path to:
- Real-world data/evidence (RWD/RWE)
- Product validation
- Algorithm training data
- Early revenue generation
- Clinician- and patient-reported outcomes
We encourage you to learn more about Cancer Commons, and we’re happy to answer questions about our organization and our Services Network. We look forward to hearing from you.